June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Phosphatidylserine (PS) is exposed in choroidal neovascular endothelium, and PS-targeting antibodies inhibit choroidal angiogenesis in vivo and ex vivo
Author Affiliations & Notes
  • Bogale Aredo
    Ophthalmology, UT Southwestern Medical Center, Dallas, TX
  • Tao Li
    Ophthalmology, UT Southwestern Medical Center, Dallas, TX
    Ophthalmology, Tongji Hospital, Tongji Medical School, Tongji, China
  • Kaiyan Zhang
    Ophthalmology, UT Southwestern Medical Center, Dallas, TX
    Ophthalmology, Hainan Provincial Peoples's Hospital, Haikou, China
  • Jose S Pulido
    Ophthalmology, Mayo Clinic, Rochester, MN
  • Shusheng Wang
    Ophthalmology, UT Southwestern Medical Center, Dallas, TX
    Cell and Molecular Biology and Ophthalmology, Tulane University, New orleans, LA
  • Philip Thorpe
    Pharmacology, UT Southwestern Medical Center, Dallas, TX
  • Rolf Brekken
    Pharmacology and Surgery, UT Southwestern Medical Center, Dallas, TX
  • Rafael Ufret-Vincenty
    Ophthalmology, UT Southwestern Medical Center, Dallas, TX
  • Footnotes
    Commercial Relationships Bogale Aredo, None; Tao Li, None; Kaiyan Zhang, None; Jose Pulido, None; Shusheng Wang, None; Philip Thorpe, None; Rolf Brekken, None; Rafael Ufret-Vincenty, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2273. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Bogale Aredo, Tao Li, Kaiyan Zhang, Jose S Pulido, Shusheng Wang, Philip Thorpe, Rolf Brekken, Rafael Ufret-Vincenty; Phosphatidylserine (PS) is exposed in choroidal neovascular endothelium, and PS-targeting antibodies inhibit choroidal angiogenesis in vivo and ex vivo. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2273. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Despite improved clinical outcomes in wet AMD brought about by anti-VEGF agents, results are still suboptimal. Additional drugs directed against different targets in the neovascular process may allow for combination therapies that improve efficacy and reduce treatment burden. The aminophospholipid phosphatidylserine (PS) may be such a target: it is almost exclusively localized to the inner leaflet of the cell membrane’s lipid bilayer in normal cells, but becomes exposed on the outer membrane in tumor neovasculature. Our goals were to: 1) determine if there is exposure of PS in choroidal neovascularization (CNV), and 2) evaluate if PS-targeting antibodies can treat CNV.

Methods: CNV was induced in B6J mice using a laser model. First, to determine if PS was exposed in the vascular endothelium of CNV lesions, we stained for PS and for ICAM-2. Confocal fluorescence microscopy was used to evaluate stained CNV lesions in RPE-choroid-scleral flat mounts, and fluorescence microscopy was used to evaluate stained CNV cross-sections. We then tested whether PS-targeting drugs could inhibit CNV growth. After induction of CNV, mice were treated either with intravitreal or intraperitoneal injections of PS-targeting antibodies vs control antibodies. CNV lesion size was then determined by ICAM-2 staining. Finally, a choroidal sprouting assay was used to determine the effect of PS targeting antibodies in a non-laser model of choroidal angiogenesis.

Results: We were able to demonstrate exposure of PS in CNV lesions, and its absence in normal choroidal and retinal vessels. PS-staining had a vascular pattern, and co-localized with ICAM-2 staining, demonstrating that PS was exposed on the choroidal neovascular endothelium. Two different PS-targeting antibodies showed a strong and reproducible inhibition of CNV when administered either intravitreally or i.p (p<0.01 vs. control). This anti-neovascular effect was also corroborated by a reduction (P<0.05) in choroidal sprouting in a non-laser ex vivo model. We also report that CNV lesions treated with PS-targeting antibodies accumulate increased density of microglia (P<0.05).

Conclusions: PS is exposed in choroidal neovasculature in both laser-induced CNV and ex vivo choroidal sprouting models. PS-targeting antibodies may be of therapeutic value in CNV.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×